I-A09

• Description:

  I-A09 and its derivatives, specifically 1,2,3-triazole-adamantylacetamide hybrids (5a–u), exhibit significant antitubercular activity. These hybrids were synthesized using copper-catalyzed click chemistry, combining bioactive fragments from antitubercular I-A09 and substituted adamantyl urea. The compound N- (1-adamantyl) -2-azido acetamide was reacted with various alkyl/aryl acetylenes to produce new analogues. Among them, N- (1-adamantan-1-yl) -2- (4- (phenanthren-2-yl) -1H-1,2,3-triazol-1-yl) acetamide (5t) showed the most promise with a minimum inhibitory concentration (MIC) of 3.12 μg/mL against Mycobacterium tuberculosis H37Rv, and a selectivity index greater than 15[1].

• UNSPSC:

  12352005

• Target:

  Bacterial

• Type:

  Reference compound

• Related Pathways:

  Anti-infection

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Infection

• Assay Protocol:

  https://www.medchemexpress.com/i-a09.html

• Smiles:

  O=C (C1=CC2=C (C=C1O) OC (C3=CC=CC=C3) =C2C4=CN (CC (NC5=CC=C (N6CCOCC6) C=C5) =O) N=N4) O

• Molecular Formula:

  C29H25N5O6

• Molecular Weight:

  539.54

• References & Citations:

  [1]Design, synthesis and evaluation of 1,2,3-triazole adamantylacetamide hybrids as potent inhibitors of Mycobacterium tuberculosis

• Shipping Conditions:

  Room temperature

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• CAS Number:

  1143579-76-3